Your browser doesn't support javascript.
Nucleoside-modified messenger RNA COVID-19 vaccine platform.
Roncati, Luca; Corsi, Lorenzo.
  • Roncati L; Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine, Institute of Pathology, University of Modena and Reggio Emilia, Modena, Italy.
  • Corsi L; Department of Life Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, Modena, Italy.
J Med Virol ; 93(7): 4054-4057, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1148833
ABSTRACT
On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic; from that date, the vaccine race has begun, and many technology platforms to develop a specific and effective COVID-19 vaccine have been launched in several clinical trials (protein subunit, RNA-based, DNA-based, replicating viral vector, nonreplicating viral vector, inactivated virus, live attenuated virus, and virus-like particle). Among the next-generation strategies, nucleoside-modified messenger RNA vaccines appear the most attractive, not only to counteract emerging pathogens but also for the possible applications in regenerative medicine and cancer therapy. However, exactly as all innovative drugs, they deserve careful pharmacovigilance in the short and long term.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26924

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26924